3SBio And AMAG Ink Deal To Develop Ferumoxytol In China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's 3SBio Pharmaceutical and U.S.-based AMAG Pharmaceuticals have entered into a strategic partnership to develop and commercialize AMAG's nanoparticle agent Ferumoxytol in China, the two companies announced May 27
You may also be interested in...
Simcere Will Co-Develop Cancer Drugs With BMS; A New R&D Model Between China And U.S.?
SHANGHAI - While reporting strong growth in the third quarter, New York-listed Chinese pharma Simcere focused attention on its recent deal with Bristol-Myers Squibb to co-develop BMS-817378, a small molecule MET/VEGFR-2 inhibitor now in preclinical development
Simcere Will Co-Develop Cancer Drugs With BMS; A New R&D Model Between China And U.S.?
SHANGHAI - While reporting strong growth in the third quarter, New York-listed Chinese pharma Simcere focused attention on its recent deal with Bristol-Myers Squibb to co-develop BMS-817378, a small molecule MET/VEGFR-2 inhibitor now in preclinical development
China's 3SBio Signs Deal For Isotechnika's Transplant/Immune System Drug Voclosporin After U.S. Delays
HONG KONG - Canada's Isotechnika Pharma has signed a new deal with Chinese drug maker 3SBio on the development and commercialization of Isotechnika's voclosporin, which helps suppress the immune system's rejection of transplanted organs